20:11 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

MacroGenics reports Phase I data of flotetuzumab for AML

MacroGenics Inc. (NASDAQ:MGNX) reported preliminary data from 8 evaluable patients with acute myelogenous leukemia (AML) in a dose-expansion cohort of a Phase I trial showing that 500 ng/kg/day IV flotetuzumab (CD3xCD123 DART molecule, MGD006, S80880)...
21:42 , Oct 27, 2017 |  BC Week In Review  |  Company News

Incyte gains rights to Macrogenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012. MacroGenics retains rights to develop combinations that include the mAb and its pipeline assets. MacroGenics is to receive...
21:31 , Oct 25, 2017 |  BC Extra  |  Company News

Incyte gains rights to MacroGenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012. MacroGenics, which retains rights to develop combinations that include the mAb and its pipeline assets, climbed...
07:00 , Jun 25, 2015 |  BC Innovations  |  Product R&D

Cellectis' UCART-ography

A year after Pfizer Inc. threw its weight behind Cellectis S.A.'s chimeric antigen receptor (CAR) T cell platform, the biotech has signed a three-year partnership with Weill Cornell Medical College to test whether its system...
07:00 , Sep 22, 2014 |  BioCentury  |  Product Development

Glenmark's new cancer BEAT

While bispecific antibodies have been around for two decades, their success in cancer has been stymied by poor in vivo properties and complex manufacturing processes. Indian biotech Glenmark Pharmaceuticals Ltd. is making a play in...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

CD3xCD123 DART molecule: Phase I started

MacroGenics began an open-label, dose-escalation, U.S. Phase I trial to evaluate MGD006 in up to 58 patients with relapsed or refractory AML. Once the maximum tolerated dose is established, the selected dose cohort will be...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

MacroGenics, Servier deal

MacroGenics said Servier exercised its option to acquire rights to develop and commercialize MGD006 outside of North America, Japan, South Korea and India. MacroGenics, which will retain rights in those regions, will receive a...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

MacroGenics preclinical data

In mice infused with primary AML xenografts, MGD006 led to a >97% reduction of AML blasts from the peripheral blood and a 40-77.8% reduction from the spleen and bone marrow at 6 weeks post-infusion. Data...
02:10 , Jan 8, 2013 |  BC Extra  |  Top Story

MacroGenics, Gilead in mAb DART deal

MacroGenics Inc. (Rockville, Md.) and Gilead Sciences Inc. (NASDAQ:GILD) partnered to develop and commercialize preclinical mAbs generated with MacroGenics' Dual-Affinity Re-Targeting (DART) technology against up to four targets. Gilead said the undisclosed targets are in...